The Worldwide Optical Preclinical Imaging Industry is Expected to Reach $859 Million by 2030 – QNT Press Release


DUBLIN, Feb. 16, 2022 /PRNewswire/ — The “Optical Preclinical Imaging Market” report has been added to’s offering.

The global optical preclinical imaging market was valued at $516.10 million in 2020, and is estimated to reach $859.70 million by 2030, growing at a CAGR of 5.2% from 2021 to 2030. Optical preclinical imaging is the visualization of living animals for research purposes, such as drug discovery and development. Imaging modalities have often been important to researchers in monitoring changes in animals responding to Physiological or environmental changes, whether at the organ, tissue, cell, or molecular level. Noninvasive and in vivo imaging methods have grown more relevant for studying animal models over time.

Optical imaging can monitor disease progression and evaluate effects of drug candidates with extremely high sensitivity. Preclinical imaging is essential for phenotyping, drug development, and providing a fundamental knowledge of disease mechanisms. The major objective is to enhance the probability of clinical success while shortening the time and expense of drug research and development. Translational research is transforming current medicine and the way health problems are handled and solved. The use of small-animal models in fundamental and preclinical sciences is a critical component of these types of research and development initiatives, serving as a link between molecular discoveries and clinical implementation in diagnostics and therapeutics.

Preclinical imaging encompasses a range of modalities, and can be broadly classified as predominantly morphological/anatomical imaging approaches or molecular imaging techniques. For anatomical imaging, techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI), and computed tomography ( CT) are commonly used, whereas optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single photon emission computed tomography (SPECT) are used for molecular visualizations. Each modality has advantages and disadvantages. Recently, multimodality devices have been designed such as SPECT/CT to give complementary information on the pathophysiological processes.

High-resolution modalities exhibit the ability to noninvasively image and monitor molecular processes within tumors, molecular imaging represents a fundamental tool for cancer scientists. The combination of high-resolution modalities such as micro-CT or micro-MRI, with highly sensitive techniques that provide functional information, such as micro-PET or micro-SPECT, continue to broaden the horizons of research in key areas such as infection, oncology, cardiology, and neurology, contributing not only for a better understanding of disease mechanisms but also for providing efficient and unique tools to evaluate new chemical entities and candidate drugs. For instance, in 2019, Kawasaki Medical University, Yokohama’s research hub…

Full story available on


Source link

Recommended For You

About the Author: News Center